Your browser is no longer supported. Please, upgrade your browser.
Settings
RNA [NASD]
Avidity Biosciences, Inc.
Index- P/E- EPS (ttm)- Insider Own0.20% Shs Outstand37.42M Perf Week-6.38%
Market Cap940.18M Forward P/E- EPS next Y-1.92 Insider Trans0.00% Shs Float32.19M Perf Month6.49%
Income- PEG- EPS next Q-0.34 Inst Own83.40% Short Float9.92% Perf Quarter-22.91%
Sales6.09M P/S154.38 EPS this Y-120.50% Inst Trans7.57% Short Ratio10.45 Perf Half Y-17.68%
Book/sh8.56 P/B2.78 EPS next Y-4.30% ROA- Target Price- Perf Year-
Cash/sh8.63 P/C2.76 EPS next 5Y- ROE- 52W Range21.70 - 37.46 Perf YTD-6.78%
Dividend- P/FCF- EPS past 5Y- ROI28.60% 52W High-36.49% Beta-
Dividend %- Quick Ratio25.20 Sales past 5Y- Gross Margin- 52W Low9.63% ATR1.72
Employees42 Current Ratio25.20 Sales Q/Q750.00% Oper. Margin- RSI (14)45.29 Volatility7.35% 6.64%
OptionableNo Debt/Eq0.00 EPS Q/Q-164.10% Profit Margin- Rel Volume1.20 Prev Close25.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume305.40K Price23.79
Recom1.70 SMA20-1.12% SMA50-6.63% SMA200-15.24% Volume365,859 Change-6.45%
Jul-07-20Initiated Wells Fargo Overweight $60
Jul-07-20Initiated Wells Fargo Overweight
Jul-07-20Initiated SVB Leerink Outperform
Jul-07-20Initiated Credit Suisse Outperform $34
Jul-07-20Initiated Credit Suisse Outperform
Jul-07-20Initiated Cowen Outperform
Feb-17-21 04:05PM  
Jan-21-21 08:30AM  
Jan-11-21 08:30AM  
Jan-08-21 08:30AM  
Dec-22-20 04:05PM  
Dec-21-20 04:05PM  
Dec-19-20 01:06PM  
Nov-10-20 04:05PM  
Nov-05-20 04:05PM  
Sep-14-20 04:05PM  
03:58PM  
Sep-08-20 08:00AM  
Sep-03-20 04:05PM  
Aug-10-20 04:05PM  
Jul-27-20 08:00AM  
Jul-23-20 08:14PM  
Jun-26-20 10:12PM  
Jun-19-20 01:24PM  
Jun-16-20 04:01PM  
Jun-12-20 11:56AM  
06:33AM  
Jun-11-20 08:54PM  
02:42PM  
06:28AM  
Jun-10-20 07:24AM  
Jun-08-20 06:55AM  
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.